Editas Medicine [EDIT] vs Vertex [VRTX] Detailed Stock Comparison

Editas Medicine Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Editas Medicine Inc. wins in 3 metrics, Vertex Pharmaceuticals Inc. wins in 14 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Editas Medicine Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) N/A 28.40 N/A
Price-to-Book Ratio 11.83 5.92 Vertex Pharmaceuticals Inc.
Debt-to-Equity Ratio 66.34 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -3.82 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -2.35 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 0.00% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -56.65% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -198.14% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -23.51% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-165.85M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 101.16% 1.24% Editas Medicine Inc.
Price-to-Sales Ratio (TTM) 7.97 9.22 Editas Medicine Inc.
Enterprise Value $220.86M $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 5.45 8.83 Editas Medicine Inc.
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) $0 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-1.80 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 2.04 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 12.23% 1.78% Vertex Pharmaceuticals Inc.

Editas Medicine Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

EDIT
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Editas Medicine Inc.-1.42%-8.44%-6.00%31.16%33.65%37.56%
Vertex Pharmaceuticals Inc.0.76%-2.49%-1.11%-12.54%-1.86%-5.98%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Editas Medicine Inc.101.16%-64.22%-89.72%-89.74%-80.34%-80.34%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Editas Medicine Inc. vs Vertex Pharmaceuticals Inc.

MetricEDITVRTX
Market Information
Market Cap i$322.98M$109.45B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,525,6511,057,061
90 Day Avg. Volume i1,591,7641,272,097
Last Close$2.78$428.34
52 Week Range$1.66 - $4.54$362.50 - $507.92
% from 52W High-38.73%-15.67%
All-Time High$99.95 (Jan 04, 2021)$519.88 (Nov 04, 2024)
% from All-Time High-97.22%-17.61%
Growth Metrics
Quarterly Revenue Growth-0.19%0.10%
Quarterly Earnings Growth-0.19%0.31%
Financial Health
Profit Margin (TTM) i0.00%0.33%
Operating Margin (TTM) i-0.57%0.40%
Return on Equity (TTM) i-1.98%0.23%
Debt to Equity (MRQ) i66.3410.91
Cash & Liquidity
Book Value per Share (MRQ)$0.28$73.49
Cash per Share (MRQ)$1.50$26.01
Operating Cash Flow (TTM) i$-165,240,992$3.63B
Levered Free Cash Flow (TTM) i$-71,477,872$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Editas Medicine Inc. vs Vertex Pharmaceuticals Inc.

MetricEDIT (Apr 22, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A28.40
Forward P/E i-3.8219.95
PEG Ratio i-3.820.88
Price to Sales (TTM) i7.979.22
Price to Book (MRQ) i11.835.92
Market Capitalization
Market Capitalization i$322.98M$109.45B
Enterprise Value i$220.86M$105.96B
Enterprise Value Metrics
Enterprise to Revenue i5.458.83
Enterprise to EBITDA i-2.3521.78
Risk & Other Metrics
Beta i2.040.37
Book Value per Share (MRQ) i$0.28$73.49

Financial Statements Comparison: Editas Medicine Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricEDIT (2025)VRTX (2025)
Revenue/Sales i40.52M12.00B
Cost of Goods Sold iN/A1.65B
COGS % of Revenue i0.0%13.8%
Gross Profit iN/A10.35B
Gross Margin i0.0%86.2%
Research & Development i89.95M4.04B
Operating Income (EBIT) i-99.34M4.55B
Operating Margin i-245.2%37.9%
EBITDA i-87.94M5.25B
EBITDA Margin i-217.0%43.7%
Pre-Tax Income i-160.06M4.64B
Pre-Tax Income % of Revenue i-395.0%38.7%
Income Tax iN/A690.00M
Income Tax % of Revenue i0.0%5.7%
Net Income (Profit) i-160.06M3.95B
Profit Margin i-395.0%32.9%

Balance Sheet & Liquidity Metrics

MetricEDIT (2025)VRTX (2025)
Cash & Equivalents i146.65M5.08B
Total Current Assets i163.90M11.20B
Total Current Assets % of Revenue i404.5%93.3%
Total Current Liabilities i46.25M3.86B
Total Current Liabilities % of Revenue i114.1%32.2%
Long-Term Debt i12.07M1.95B
Long-Term Debt % of Revenue i29.8%16.3%
Total Shareholders Equity i27.29M18.67B
Retained Earnings i-1.63B13.56B
Retained Earnings % of Revenue i-4,019.0%113.0%
Property, Plant & Equipment i37.68M1.56B

Cash Flow Statement Comparison

MetricEDIT (2025)VRTX (2025)
Operating Cash Flow i-158.17M3.77B
Operating Cash Flow % of Revenue i-390.3%31.4%
Capital Expenditures i-338,000-437.60M
Free Cash Flow i-165.85M3.19B
FCF Margin i-409.3%26.6%
Debt Repayment iN/A-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricEDITVRTX
Shares Short i11.94M4.02M
Short Ratio i6.642.80
Short % of Float i12.23%1.78%
Shares Outstanding i97.87M253.99M
Float Shares i97.51M253.24M
% Held by Insiders i0.27%0.21%
% Held by Institutions i53.11%97.60%
% Held by Public i46.62%2.19%

Dividend Analysis & Yield Comparison: Editas Medicine Inc. vs Vertex Pharmaceuticals Inc.

MetricEDITVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A